Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab
given via subconjunctival injection in patients undergoing corneal transplantation.